ArticleFrontiers in psychiatry2026
Group metacognitive therapy for students with anxiety: an uncontrolled pre-post study of feasibility and associated outcomes.
Article in Frontiers in psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Group-based Metacognitive Therapy (gMCT) has shown promising results for anxiety, but research specifically targeting student populations is limited. By addressing maladaptive metacognitions, gMCT aims to reduce core symptoms such as anxiety, excessive worry, and rumination. More research is needed in university settings to determine whether gMCT can be successfully applied to students. Method: We investigated the feasibility and examined a gMCT treatment course with an uncontrolled pre-post design with a 3-month booster follow-up. The design reflects the available data material and the limitations of the real-world clinic setting. Participants were students with a score >=10 on GAD-7 assessment, or diagnosed with anxiety disorders, including Generalized Anxiety Disorder (GAD), Social Anxiety Disorder (SAD), and Panic Disorder (PD). Patients presenting with additional conditions that would necessitate alternative interventions/treatment were excluded and not eligible for this study. The generic MCT treatment model was delivered as part of routine care by therapists at the Oslo Student Welfare Organization (SiO Helse) who had relevant MCT training. Data material was collected at pre-treatment, post-treatment, and booster follow-ups. Feasibility was assessed using attendance, dropout, and number of completers. Missing data were handled using multilevel modelling and mean imputation at the item level. The primary outcome was GAD-7, and depressive symptoms (secondary outcome) with the PHQ-9. Worry and Metacognitive beliefs were assessed. Analyses included paired sample t-tests, clinically significant change analysis, and multilevel modelling (MLM) to evaluate change over time. Results: Treatment adherence was high, with participants attending an average of 7.1 out of 8 sessions. Significant reductions were observed across all measures from pre- to post-assessment, with large effect sizes for the primary outcome (GAD-7) and for worry (CAS-1), negative metacognitions (MCQ-30), and depressive symptoms (PHQ-9). These improvements were maintained at the 3-month booster follow-up. Conclusion: gMCT is feasible for treating student populations with anxiety and depression symptoms. Overall, 77.3% of participants improved or recovered after post-assessment. The results should be cautiously interpreted due to the single-site setting, few patients and short follow-up period, but suggest that other student welfare organizations may benefit from implementing gMCT to treat anxiety- and worry-related problems in student populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.